This trial is evaluating whether mRNA-1273 will improve 3 primary outcomes and 1 secondary outcome in patients with Lymphoma. Measurement will happen over the course of 14 months.
This trial requires 220 total participants across 2 different treatment groups
This trial involves 2 different treatments. MRNA-1273 is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Findings from a recent study suggests that MM incidence is relatively constant in the United States, although in some parts of the country, incidence may be significantly increased. Furthermore, MM seems to be increasing in some states. Findings from a recent study suggest that the data from MM-HOD may be skewed since patients with MM were excluded from the analysis. Despite these limitations, our analysis still suggests an MM incidence that is similar to that of previous studies in other geographic areas." - Anonymous Online Contributor
"Currently, there are not any agents on the market that can cure myeloma. There are three approaches to myeloma therapy: observation, targeted therapy based on bortezomib, and induction and maintenance therapy with BZDs and ASCT. If there is no indication of treatment or an effective response to therapy, transplantation can be attempted in a selected group of patients with minimal disease." - Anonymous Online Contributor
"Multiple myeloma is an aggressive cancer that is a disease that is associated with an increased rate of skeletal fractures, blood clotting problems and increased risk of death. Multiple myeloma can be prevented through a number of measures for prevention, early detection and management of the disease." - Anonymous Online Contributor
"There is significant variability in the treatment given to MM patients and the type of therapy, with a number of options available. Treatment is reliant on the diagnosis and the stage of the disease. A number of factors such as age, function, weight, and comorbid conditions are considered when managing treatment." - Anonymous Online Contributor
"In a country where multiple myeloma accounts for less than 1% of all malignancies, these data suggest that screening of an otherwise healthy person for multiple myeloma should be offered to all older women." - Anonymous Online Contributor
"Both mrna-1273 and mrna-2905 could be used in the treatment of myeloma patients, but there were minimal differences in the clinical responses and overall survival between these two protocols. Further studies are required to establish mrna-1273 as an additional treatment component in myeloma patients, and the clinical outcomes for this combination seem satisfactory." - Anonymous Online Contributor
"The number of patients is not significant enough at present for randomized treatments. Although it is necessary to test new medications, the new data need to be tested in patients. In addition, new clinical drugs will need to be tested to find the best way to treat multiple myeloma." - Anonymous Online Contributor
"In a recent study, findings of a large number of patients with multiple myeloma, the primary cause of the disease was biclonal gammopathy of undetermined significance. The development of multiple myeloma from biclonal gammopathy of undetermined significance was associated with IgM and IgG b-cells." - Anonymous Online Contributor
"Those with MM treated with mrnaside therapy had a statistically significant improvement in quality of life after 6 months compared with conventional treatment, as measured using a quality of life questionnaire." - Anonymous Online Contributor
"Results from a recent paper provide clinical evidence that RNAi may be a useful therapy as a monotherapeutic agent for the treatment of multiple myeloma-related disease." - Anonymous Online Contributor
"This pedigree expands upon previous observational studies, indicating that multiple myeloma is a heritable disease. Results from a recent clinical trial also suggests that the prevalence of multiple myeloma may vary between geographic regions." - Anonymous Online Contributor